City Therapeutics and Iambic line up Nasdaq IPOs
City Therapeutics, an RNAi developer led by former Alnylam executives, is seeking a $158 million IPO through the sale of 9.72 million shares at $17 each. Iambic is aiming for a $135 million Nasdaq debut. The news roundup also covers Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq.
City Therapeutics, which works on RNAi therapies, is led by people who previously worked at Alnylam. It is pursuing a Nasdaq IPO that would raise $158 million by selling 9.72 million shares at $17 each.
Iambic is also preparing a Nasdaq listing and aims to raise $135 million. The same news roundup also includes Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio, and Tecentriq.
If these offerings proceed, they may give the companies capital to advance RNAi and other drug programs, potentially affecting patients who could benefit from new therapies. Investors and employees may be affected by public-market scrutiny and funding access. The roundup’s other items suggest broader biotech financing activity, which could influence research priorities and treatment availability, though outcomes remain uncertain.